Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (1): 16-22    DOI: 10.31083/j.ejgo.2020.01.4731
Original Research Previous articles | Next articles
High-grade endometrial cancer survival (endometrioid to non-endometrioid histology comparison)
S. Srdelić Mihalj1, *(), V. Čapkun2, I. Kuzmić-Prusac3
1 Department of Gynecology, Split University Hospital Center, Split, Croatia
2 Department of Nuclear Medicine, Split University Hospital Center, Split, Croatia
3 Department of Pathology, Split University Hospital Center, Split, Croatia
Download:  PDF(737KB)  ( 367 ) Full text   ( 11 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of Investigation: To analyze overall survival (OS) and disease-free survival (DFS) in a retrospective series of 125 patients with serous, clear cell, and high-grade endometrioid carcinoma having undergone complete treatment (primary surgery, oncology treatments, and follow up) at the present institution. Materials and Methods: All women with high-grade endometrial cancer having undergone surgery (1998-2012) and postoperatively treated and monitored at Split University Hospital Center, whose tissue samples were stored at Department of Pathology, Split University Hospital Center, were included in the study. Survival time was analyzed with Kaplan- Meier method and the log-rank test was used to assess between-group differences. Cox proportional hazard regression model was used on multivariate survival analysis. Patients were followed from the time of primary surgery until death or last follow up in December 2015. Results: Women with serous and clear cell endometrial cancer had similar survival compared to those with high-grade endometrioid endometrial cancer. On multivariate analysis, only earlier stage was an independent predictor of improved survival. Conclusions: The present findings suggest that serous and clear cell endometrial carcinomas have a similar prognosis compared to high-grade endometrioid carcinoma of the uterus.
Key words:  Uterine cancer      High-grade endometrial cancer      Serous endometrial cancer      Clear cell endometrial cancer      Survival     
Published:  15 February 2020     
*Corresponding Author(s):  S. SRDELIĆ MIHALJ     E-mail:  ssrdelic@globalnet.hr
About author:  Contributed equally.

Cite this article: 

S. Srdelić Mihalj, V. Čapkun, I. Kuzmić-Prusac. High-grade endometrial cancer survival (endometrioid to non-endometrioid histology comparison). European Journal of Gynaecological Oncology, 2020, 41(1): 16-22.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.01.4731     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I1/16

[1] Ji Geun Yoo, Hae Nam Lee, Sung Jong Lee, Jin Hwi Kim, Yong Seok Lee, Ahwon Lee, Soo Young Hur, Keun Ho Lee. Germline BRCA2 mutation is associated with greater progression-free survival in korean women with advanced high-grade serous ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 675-680.
[2] Michelle F. Benoit, Kristy K. Ward. Uterine Cancer Normogram to Predict Lymph Node Metastasis: Comparison to the Mayo Algorithm and an External Validation of a Model in a North American Population[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 681-684.
[3] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[4] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[5] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[6] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[7] Xiaofeng Xu, Xuan Zhou, Yijin Wang, Tao Liu, Jian Fu, Qian Yang, Jun Wu, Huaijun Zhou. Survival-associated transcriptome analysis in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 455-461.
[8] M.E. Căpîlna, B. Szabo, J. Becsi, M. Morariu, M. Gheorghe, S.L. Kiss, B. Moldovan. Surgical complications and survival after pelvic exenteration: our experience following 60 procedures[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 171-175.
[9] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[10] S.H. Nam, H.R. Yang, D. Kang, K.O. Jung, W.Y. Kim. Survival of advanced epithelial ovarian/fallopian tube/primary peritoneum carcinoma after high-complexity upper abdominal surgery[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 970-976.
[11] Z. Zheng, Z.H. Han, Z.T. Li, X.H. Wu. The impact of laparoscopic surgical treatments on oncologic outcome of Stage I uterine leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 977-981.
[12] A.C. da Silva, T. Calapodopulos, T.C. Guaresqui, J. C. Saldanha, E.F.C. Murta, R.S. Nomelini. Uterine smooth muscle tumor of uncertain malignant potential[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1070-1072.
[13] S. Dierckxsens, B. Geerinckx, M.T. Huizing, W.A.A. Tjalma. A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 714-721.
[14] H. Oikiri, M. Futagami, J. Watanabe, Y. Yokoyama. Adenocarcinoma of the cervix: its prognosis and difficult pathological diagnosis[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 728-733.
[15] G. Scandurra, S. Gieri, F. Marletta, B. Pecorino, S. Nicolini, G. L. Banna, G. Scibilia, P. Scollo. Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrent ovarian cancer patients with BRCA1/2 mutation[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 739-743.
No Suggested Reading articles found!